DIM 📈 Sartorius Stedim Biotech SA - Overview
Exchange: PA • Country: France • Currency: EUR • Type: Common Stock • ISIN: FR0013154002
DIM: Instruments, Consumables, Bioreactors, Pipettes, Sensors, Analyzers, Software
Sartorius Stedim Biotech SA is a leading global provider of innovative solutions for the biopharmaceutical industry, with a comprehensive portfolio of products and services that cater to the diverse needs of its clients. The company's product range includes cell lines, cell culture media, bioreactors, and advanced therapies, as well as a broad array of products for separation, purification, and concentration processes. Additionally, it offers products and systems for the storage and transportation of intermediate and finished biological products, ensuring the integrity and safety of these sensitive materials throughout the entire production process.
The company's service offerings are equally extensive, encompassing cell cultivation, fermentation, separation, purification, and fluid management services that enable biopharmaceutical manufacturers to optimize their production workflows. Sartorius Stedim Biotech SA also provides a range of analytical instruments, including biolayer interferometry instruments, microbiology enumeration, sterility testing, and air monitoring instruments, which are essential for ensuring the quality and purity of biopharmaceutical products. Furthermore, the company offers pipette products, sensors and analyzers, biomolecule analysis tools, flow cytometry, batch and intensified chromatography systems, and lab data and fleet management software, all of which are designed to streamline laboratory operations and improve productivity.
In terms of its software capabilities, Sartorius Stedim Biotech SA offers data analytics software that enables biopharmaceutical manufacturers to model and optimize their production processes, as well as a process automation platform and software that facilitates the integration of various production systems. The company also develops and produces transfection reagents and other DNA/RNA delivery reagents, as well as plasmid DNA, which are critical components in the production of biopharmaceuticals. With a diverse client base that includes manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories, Sartorius Stedim Biotech SA is well-positioned to address the complex needs of the biopharmaceutical industry.
As a subsidiary of Sartorius AG, Sartorius Stedim Biotech SA leverages its parent company's resources and expertise to drive innovation and growth. With a history dating back to 1978, the company has established itself as a trusted partner to the biopharmaceutical industry, with a strong commitment to quality, safety, and customer satisfaction. Headquartered in Aubagne, France, Sartorius Stedim Biotech SA operates globally, with a web presence at https://www.sartorius.com, and is listed on the stock exchange with the ISIN code FR0013154002, classified as a common stock under the GICS Sub Industry of Health Care Equipment.
Additional Sources for DIM Stock
DIM Stock Overview
| Market Cap in USD | 19,641m |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| GiC Sub-Industry | Health Care Equipment |
| IPO / Inception |
DIM Stock Ratings
| Growth 5y | -10.5% |
| Fundamental | 28.0% |
| Dividend | 49.2% |
| Rel. Strength Industry | -1069 |
| Analysts | - |
| Fair Price Momentum | 162.72 EUR |
| Fair Price DCF | 104.48 EUR |
DIM Dividends
| Dividend Yield 12m | 0.37% |
| Yield on Cost 5y | 0.48% |
| Annual Growth 5y | 20.36% |
| Payout Consistency | 84.7% |
DIM Growth Ratios
| Growth Correlation 3m | -10.2% |
| Growth Correlation 12m | -63.9% |
| Growth Correlation 5y | -32.5% |
| CAGR 5y | 4.90% |
| CAGR/Mean DD 5y | 0.15 |
| Sharpe Ratio 12m | -0.47 |
| Alpha | -47.03 |
| Beta | 0.80 |
| Volatility | 42.15% |
| Current Volume | 113.3k |
| Average Volume 20d | 57.6k |
As of December 21, 2024, the stock is trading at EUR 185.20 with a total of 113,314 shares traded.
Over the past week, the price has changed by -4.98%, over one month by +10.22%, over three months by +2.04% and over the past year by -22.58%.
Neither. Based on ValueRay Fundamental Analyses, Sartorius Stedim Biotech SA is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 27.98 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of DIM as of December 2024 is 162.72. This means that DIM is currently overvalued and has a potential downside of -12.14%.
Sartorius Stedim Biotech SA has no consensus analysts rating.
According to ValueRays Forecast Model, DIM Sartorius Stedim Biotech SA will be worth about 178.1 in December 2025. The stock is currently trading at 185.20. This means that the stock has a potential downside of -3.83%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 222.5 | 20.2% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 178.1 | -3.8% |